NCT02667132

Brief Summary

The aim of this study was to retrospectively review the granulomatous mastitis and evaluated current approach and treatment. HYPOTHESIS Although there is no common protocol for the treatment and management process of GM, the ternary treatment (medical treatment following by surgical procedure, Steroid+Antibiotic and surgical procedure, respectively) is considered as the most successful treatment approach.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 11, 2016

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 28, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 3, 2018

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 4, 2018

Completed
Last Updated

February 20, 2018

Status Verified

February 1, 2018

Enrollment Period

2.1 years

First QC Date

January 11, 2016

Last Update Submit

February 18, 2018

Conditions

Keywords

Granulomatous, MastitisC17.800.090.968.400C13.703.844.603.400

Outcome Measures

Primary Outcomes (1)

  • Granulomatous Mastitis Working Group

    The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease. A shared excel file at the following website http://sanko.edu.tr/GranulamatozMastit has been created to record the data simultaneously. Each researcher can add the data at the file by using username and password. After data collection, statistical analysis will include Mann-Whitney U test, student's t test and chi-square test and statistical significance will set at P\< 0.05.The sample size and power analysis were conducted and the results indicated that at least 100 samples in each group are required to achieve the statistical significance at P\< 0.05 with 90% power. The estimated total cases are expected over 400 cases.

    dec 2015 start data collection, February 2016 The primary outcome statement - April 2016 end up study

Study Arms (3)

medical treatment

In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate

surgical treatment

lumpectomy, mastectomy, abscess drainage

surgical+medical treatment

first medical, after surgical treatment or first surgical, after medical treatment

Eligibility Criteria

Age18 Years - 90 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

from 18 to 90 years womens with Granulomatous Mastitis

You may qualify if:

  • All Granulomatous Mastitis

You may not qualify if:

  • Breast Carcinoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Atilla Soran

Pittsburgh, Pennsylvania, 15261, United States

Location

Related Publications (2)

  • Lee JH, Oh KK, Kim EK, Kwack KS, Jung WH, Lee HK. Radiologic and clinical features of idiopathic granulomatous lobular mastitis mimicking advanced breast cancer. Yonsei Med J. 2006 Feb 28;47(1):78-84. doi: 10.3349/ymj.2006.47.1.78.

  • Kok KY, Telisinghe PU. Granulomatous mastitis: presentation, treatment and outcome in 43 patients. Surgeon. 2010 Aug;8(4):197-201. doi: 10.1016/j.surge.2010.02.002. Epub 2010 Mar 6.

MeSH Terms

Conditions

Granulomatous Mastitis

Condition Hierarchy (Ancestors)

MastitisPuerperal DisordersPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Atilla Soran, Professor

    Granulomatous Mastitis Working Group

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2016

First Posted

January 28, 2016

Study Start

December 1, 2015

Primary Completion

January 3, 2018

Study Completion

January 4, 2018

Last Updated

February 20, 2018

Record last verified: 2018-02

Data Sharing

IPD Sharing
Will share

DATA COLLECTION A shared excel file at the following website http://sanko.edu.tr/GranulamatozMastit has been created to record the data simultaneously. Each researcher can add the data at the file by using username and password. After data collection, the data will be presented mean+StDv. Statistical analysis will include Mann-Whitney U test, student's t test and chi-square test and statistical significance will set at P\< 0.05. The treatment group in this study will be divided as medical, surgical and medical+surgical and the comparison among these groups will be conducted to reach the aims determined in expected outcomes section. The sample size and power analysis were conducted and the results indicated that at least 100 samples in each group are required to achieve the statistical significance at P\< 0.05 with 90% power. The estimated total cases are expected over 400 cases.

Locations